Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients - Institut Pierre Louis d'Epidémiologie et de Santé Publique Accéder directement au contenu
Article Dans Une Revue Annals of Oncology Année : 2021

Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients

Résumé

Active cancer and ongoing antineoplastic treatments are major factors for severe COVID-19 and death, reasons why the SARS-CoV-2 vaccination remains a priority in cancer patients (CPs). However, immunocompromised patients were excluded from major studies on mRNA vaccines, and could have a decreased response to vaccination, as recently demonstrated in solid organ transplant recipients. Herein, we aimed to assess the proportion of antibody response 4 weeks after the first injection of the BNT162b2 (Pfizer-BioNTech) vaccine in CPs and health care workers (HCWs) as the control population.
Fichier principal
Vignette du fichier
Palich et al. - 2021 - Weak immunogenicity after a single dose of SARS-Co.pdf (216.23 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03220233 , version 1 (07-05-2021)

Identifiants

Citer

Romain Palich, M. Veyri, S. Marot, A. Vozy, J. Gligorov, et al.. Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients. Annals of Oncology, inPress, ⟨10.1016/j.annonc.2021.04.020⟩. ⟨hal-03220233⟩
32 Consultations
46 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More